141 related articles for article (PubMed ID: 11884389)
1. Inhibition of lipid raft-dependent signaling by a dystrophy-associated mutant of caveolin-3.
Carozzi AJ; Roy S; Morrow IC; Pol A; Wyse B; Clyde-Smith J; Prior IA; Nixon SJ; Hancock JF; Parton RG
J Biol Chem; 2002 May; 277(20):17944-9. PubMed ID: 11884389
[TBL] [Abstract][Full Text] [Related]
2. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.
Smythe GM; Eby JC; Disatnik MH; Rando TA
J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.
Galbiati F; Volonte D; Minetti C; Chu JB; Lisanti MP
J Biol Chem; 1999 Sep; 274(36):25632-41. PubMed ID: 10464299
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.
Sotgia F; Woodman SE; Bonuccelli G; Capozza F; Minetti C; Scherer PE; Lisanti MP
Am J Physiol Cell Physiol; 2003 Nov; 285(5):C1150-60. PubMed ID: 12839838
[TBL] [Abstract][Full Text] [Related]
5. Caveolae and caveolin-3 in muscular dystrophy.
Galbiati F; Razani B; Lisanti MP
Trends Mol Med; 2001 Oct; 7(10):435-41. PubMed ID: 11597517
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol and fatty acids regulate dynamic caveolin trafficking through the Golgi complex and between the cell surface and lipid bodies.
Pol A; Martin S; Fernández MA; Ingelmo-Torres M; Ferguson C; Enrich C; Parton RG
Mol Biol Cell; 2005 Apr; 16(4):2091-105. PubMed ID: 15689493
[TBL] [Abstract][Full Text] [Related]
7. Long-chain fatty acid uptake into adipocytes depends on lipid raft function.
Pohl J; Ring A; Ehehalt R; Schulze-Bergkamen H; Schad A; Verkade P; Stremmel W
Biochemistry; 2004 Apr; 43(14):4179-87. PubMed ID: 15065861
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities.
Galbiati F; Engelman JA; Volonte D; Zhang XL; Minetti C; Li M; Hou H; Kneitz B; Edelmann W; Lisanti MP
J Biol Chem; 2001 Jun; 276(24):21425-33. PubMed ID: 11259414
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-3 deficiency causes muscle degeneration in mice.
Hagiwara Y; Sasaoka T; Araishi K; Imamura M; Yorifuji H; Nonaka I; Ozawa E; Kikuchi T
Hum Mol Genet; 2000 Dec; 9(20):3047-54. PubMed ID: 11115849
[TBL] [Abstract][Full Text] [Related]
10. Conformational defects slow Golgi exit, block oligomerization, and reduce raft affinity of caveolin-1 mutant proteins.
Ren X; Ostermeyer AG; Ramcharan LT; Zeng Y; Lublin DM; Brown DA
Mol Biol Cell; 2004 Oct; 15(10):4556-67. PubMed ID: 15304521
[TBL] [Abstract][Full Text] [Related]
11. Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation.
Watson RT; Shigematsu S; Chiang SH; Mora S; Kanzaki M; Macara IG; Saltiel AR; Pessin JE
J Cell Biol; 2001 Aug; 154(4):829-40. PubMed ID: 11502760
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy.
Herrmann R; Straub V; Blank M; Kutzick C; Franke N; Jacob EN; Lenard HG; Kröger S; Voit T
Hum Mol Genet; 2000 Sep; 9(15):2335-40. PubMed ID: 11001938
[TBL] [Abstract][Full Text] [Related]
13. The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction.
Schlegel A; Lisanti MP
Cytokine Growth Factor Rev; 2001 Mar; 12(1):41-51. PubMed ID: 11312118
[TBL] [Abstract][Full Text] [Related]
14. The Caveolin genes: from cell biology to medicine.
Williams TM; Lisanti MP
Ann Med; 2004; 36(8):584-95. PubMed ID: 15768830
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-3 in muscular dystrophy.
McNally EM; de Sá Moreira E; Duggan DJ; Bönnemann CG; Lisanti MP; Lidov HG; Vainzof M; Passos-Bueno MR; Hoffman EP; Zatz M; Kunkel LM
Hum Mol Genet; 1998 May; 7(5):871-7. PubMed ID: 9536092
[TBL] [Abstract][Full Text] [Related]
16. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.
Volonte D; Peoples AJ; Galbiati F
Mol Biol Cell; 2003 Oct; 14(10):4075-88. PubMed ID: 14517320
[TBL] [Abstract][Full Text] [Related]
17. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.
Galbiati F; Volonte D; Minetti C; Bregman DB; Lisanti MP
J Biol Chem; 2000 Dec; 275(48):37702-11. PubMed ID: 10973975
[TBL] [Abstract][Full Text] [Related]
18. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane.
Wyse BD; Prior IA; Qian H; Morrow IC; Nixon S; Muncke C; Kurzchalia TV; Thomas WG; Parton RG; Hancock JF
J Biol Chem; 2003 Jun; 278(26):23738-46. PubMed ID: 12692121
[TBL] [Abstract][Full Text] [Related]
19. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle.
Matsuda C; Hayashi YK; Ogawa M; Aoki M; Murayama K; Nishino I; Nonaka I; Arahata K; Brown RH
Hum Mol Genet; 2001 Aug; 10(17):1761-6. PubMed ID: 11532985
[TBL] [Abstract][Full Text] [Related]
20. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains.
Roy S; Luetterforst R; Harding A; Apolloni A; Etheridge M; Stang E; Rolls B; Hancock JF; Parton RG
Nat Cell Biol; 1999 Jun; 1(2):98-105. PubMed ID: 10559881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
